IntroductionStudy aimed to determine the occurrence of 5 thrombosis-related single-nucleotide polymorphisms (SNPs) in patients with venous thromboembolism (VTE) (n = 2630) and a control group (n = 2637) in the Czech population.MethodsThe following gene SNPs were detected in both groups: F5 Leiden (rs6025), F2 (rs1799963), FGG, fibrinogen gamma' (rs2066865), F11 (rs2289252) and ABO (rs8176719). Statistical analysis was performed using SAS statistical software with population genetics tools.ResultsHeterozygotes for F5 Leiden were associated with a 5.58-fold and homozygotes F5 Leiden with a 33.46-fold increased risk of VTE. At SNP rs1799963 (F2, prothrombin), only heterozygotes had a significant 3.9-fold increased risk of VTE. The findings at SNP rs2066865 (fibrinogen gamma', FGG) showed a 1.37-fold increased risk of VTE for FGG heterozygotes and a 1.77-fold increased risk of VTE for FGG homozygotes. There is also a significant 1.42-fold increase risk of VTE in the heterozygotes and a 1.80-fold increase risk of VTE in the homozygotes of the SNP rs 2289252 (F11). Further higher increases in the risk of VTE in both variants were found in patients with VTE at rs8176719 (ABO, non-O). It corresponds to a 2.2-fold increase in the risk of VTE in heterozygotes and a 3.5-fold increase in the risk of VTE in homozygotes.ConclusionBesides F5 Leiden and prothrombin mutation, the study suggests that the gene polymorphisms of FGG (rs2066865), F11 (rs2289252) and ABO (rs8176719) play a role as an independent heritable risk factor for VTE in the Czech population.

1st Department of Medicine Division of Hematology first Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Center for Cardiovascular Prevention first Faculty of Medicine Charles University and Thomayer University Hospital Prague Czech Republic

Department of Blood Transfusion first Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Thrombotic Centre Institute of Medical Biochemistry and Laboratory Diagnostics first Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Zobrazit více v PubMed

Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756–764. PubMed

Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41:3–14. PubMed PMC

ISTH Steering Committee for World Thrombosis Day. Thrombosis: A major contributor to the global disease burden. J Thromb Haemost. 2014;12:1580–1590. PubMed

Bell EJ, Lutsey PL, Basu Set al. et al. Lifetime risk of venous thromboembolism in two cohort studies. Am J Med. 2016;129(339):e19–e26. PubMed PMC

Heit JA, Ashrani A, Crusan DJ, McBane RD, Petterson TM, Bailey KR. Reasons for the persistent incidence of venous thromboembolism. Thromb Haemost. 2017;117:390–400. PubMed PMC

Farrell JJ, Sutter C, Tavri S, Patel I. Incidence, and interventions for post-thrombotic syndrome. Cardiovasc Diagn Ther. 2016;6:623–631. PubMed PMC

Konstantinides SV, Meyer G, Becattini C, et al. ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J. 2019;2020(41):543–603. PubMed

Jansa P, Ambrož D, Kuhn M, et al. Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic. Pulm Circ. 2022;12(1):e12038. PubMed PMC

Klok FA, Ageno W, Ay C, et al. Optimal follow-up after acute pulmonary embolism: A position paper of the European Society of Cardiology working group on pulmonary circulation and right ventricular function, in collaboration with the European Society of Cardiology working group on atherosclerosis and vascular biology, endorsed by the European respiratory society. Eur Heart J. 2022;43:183–189. PubMed PMC

Kyrle PA, Kammer M, Eischer L, et al. The long-term recurrence risk of patients with unprovoked venous thromboembolism: An observational cohort study. J Thromb Haemost. 2016;14:2402–2409. PubMed

Jiménez D, Díaz G, Marín E, Vidal R, Sueiro A, Yusen RD. The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism. Thromb Haemost. 2006;95:562–566. PubMed

Kearon C. Extended anticoagulation for unprovoked venous thromboembolism: A majority of patients should be treated. J Thromb Thrombolysis. 2011;31:295–300. PubMed

Barco S, Corti M, Trinchero A, et al. Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism. J Thromb Haemost. 2017;15:1436–1442. PubMed

Rosendaal F. Venous thrombosis: A multicausal disease. Lancet 1999;353(9159):1167–1173. PubMed

Zöller B, Svensson PJ, Dahlbäck B, Lind-Hallden C, Hallden C, Elf J. Genetic risk factors for venous thromboembolism. Expert Rev Hematol. 2020;13:971–981. PubMed

de Haan HG, Bezemer ID, Doggen CJ, et al. Multiple SNP testing improves risk prediction of first venous thrombosis. Blood. 2012;120:656–663. PubMed

van Hylckama Vlieg A, Flinterman LE, Bare LA, et al. Genetic variations associated with recurrent venous thrombosis. Circ Cardiovasc Genet. 2014;7:806–813. PubMed

Klarin D, Busenkell E, Judy R, et al. Genome- wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. Nat Genet. 2019;51:1574–1579. PubMed PMC

Lindström S, Wang L, Smith EN, et al. Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. Blood. 2019;134:1645–1657. PubMed PMC

Thibord F, Klarin D, Brody JA, et al. Cross-ancestry investigation of venous thromboembolism genomic predictors. Circulation. 2022;146:1225–1242. PubMed PMC

Ghouse J, Tragante V, Ahlberg G, et al. Genome-wide meta-analysis identifies 93 risk loci and enables risk prediction equivalent to monogenic forms of venous thromboembolism. Nat Genet. 2023;55(3):399–409. PubMed

Folsom AR, Tang W, Hong CPet al. et al. Prediction of venous thromboembolism incidence in the general adult population using two published genetic risk scores. PLoS One. 2023;18(1):e0280657. PubMed PMC

Tang W, Teichert M, Chasman DI, et al. A genome-wide association study for venous thromboembolism: The extended cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Genet Epidemiol. 2013;37:512–521. PubMed PMC

Mannucci PM, Franchini M. Classic thrombophilic gene variants. Thromb Haemost. 2015;114:885–889. PubMed

Zhang Z, Li H, Weng H, et al. China Pulmonary thromboembolism REgistry study (CURES) investigators. Genome-wide association analyses identified novel susceptibility loci for pulmonary embolism among han Chinese population. BMC Med. 2023;21(1):153. PubMed PMC

Liu C, Hou J, Li Wet al. Construction and optimization of a polygenic risk model for venous thromboembolism in the Chinese population. J Vasc Surg Venous Lymphat Disord. 2024;12(1):101666. PubMed PMC

Cífková R, Bruthans J, Wohlfahrt P, et al. 30 - year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post-MONICA, 1985-2016/17. PLoS One. 2020;15:e0232845. PubMed PMC

Rinde LB, Morelli VM, Småbrekke B, et al. Effect of prothrombotic genotypes on the risk of venous thromboembolism in patients with and without ischemic stroke. The tromsø study. J Thromb Haemost. 2019;17:749–758. PubMed

Skille H, Paulsen B, Hveem K, et al. Combined effects of five prothrombotic genotypes and cancer on the risk of a first venous thromboembolic event. J Thromb Haemost. 2020;18:2861–2869. PubMed

Kvasnička J, Jansa P, Cífková Ret al. The incidence of the thrombophilic SNPs rs6025, rs1799963, rs2066865, rs2289252, and rs8176719 in chronic thromboembolic pulmonary hypertension. Clin Appl Thromb Hemost. 2024;30:10760296241271369. PubMed PMC

Bare LA, de Haan HG, Arellano AR, Tong C H, Devlin JJ, Rosendaal FR. A simple genetic thrombosis score of five single nucleotide polymorphisms is associated with risk of first venous thrombosis in pregnant women. Blood. 2013;122(21):3617.

Trégouët DA, Heath S, Saut N, et al. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: Results from a GWAS approach. Blood. 2009;113:5298–5303. PubMed

Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369(6475):64–67. PubMed

Kvasnicka T, Hajkova J, Bobcikova P, et al. The frequencies of six important thrombophilic mutations in a population of the Czech Republic. Physiol Res. 2014;63:245–253. PubMed

Kvasnicka J. Hereditary thrombophilias-recommendations for genetic testing in the clinical praxis. Cas Lek Cesk. 2010;149:468–471. PubMed

Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'- untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–3703. PubMed

Ceelie H, Spaargaren-van Riel CC, Bertina RM, Vos HL. G20210a is a functional mutation in the prothrombin gene; effect on protein levels and 3'-end formation. J Thromb Haemost. 2004;2:119–127. PubMed

Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood. 2005;106:4176–4183. PubMed

Uitte de Willige S, Rietveld IM, De Visser MC, Vos HL, Bertina RM. Polymorphism 10034 C> T is located in a region regulating polyadenylation of FGG transcripts and influences the fibrinogen gamma'/gammaA mRNA ratio. J Thromb Haemost. 2007;5:1243–1249. PubMed

Li Y, Bezemer ID, Rowland CM, et al. Genetic variants associated with deep vein thrombosis: The F11 locus. J Thromb Haemost. 2009;7:1802–1808. PubMed

Lunghi B, Cini M, Legnani C, Bernardi F, Marchetti G. The F11 rs2289252 polymorphism is associated with FXI activity levels and APTT ratio in women with thrombosis. Thromb Res. 2012;130:563–564. PubMed

Gailani D, Gruber A. Targeting factor XI and factor XIa to prevent thrombosis. Blood. 2024;143:1465–1475. PubMed PMC

Yamamoto F, Clausen H, White T, Marken J, Hakomori S. Molecular genetic basis of the histo-blood group ABO system. Nature. 1990;345(6272):229–233. PubMed

Groot HE, Villegas Sierra LE, Said MA, Lipsic E, Karper JC, van der Harst P. Genetically determined ABO blood group and its associations with health and disease. Arterioscler Thromb Vasc Biol. 2020;40:830–838. PubMed

Sabater-Lleal M, Huffman JE, de Vries PS, et al. Genome-wide association transethnic meta-analyses identifies novel associations regulating coagulation factor VIII and von willebrand factor plasma levels. Circulation. 2019;139:620–635. PubMed PMC

Michels A, Lillicrap D, Yacob M. Role of von willebrand factor in venous thromboembolic disease. JVS Vasc Sci. 2021;3:17–29. PubMed PMC

Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343:457–462. PubMed

Folsom AR, Tang W, Weng LCet al. et al. Replication of a genetic risk score for venous thromboembolism in whites but not in African Americans. J Thromb Haemost. 2016;14:83–88. PubMed PMC